Drug Database
GL

glimepiride + metformin SR (Amaryl Mex / Amaryl M SR)

✓ Approved

Sanofi S.A · KCNJ11 · Small Molecule

What is glimepiride + metformin SR?

glimepiride + metformin SR is a small molecule developed by Sanofi S.A. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesAmaryl Mex, Amaryl M SR
CompanySanofi S.A
Drug ClassSmall Molecule
Molecular TargetKCNJ11, ABCC8
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Mechanism of Action

Molecular Targets

glimepiride + metformin SR acts on 2 molecular targets:

KCNJ11potassium inwardly rectifying channel subfamily J member 11 (BIR, HHF2)
ABCC8ATP binding cassette subfamily C member 8 (MRP8, SUR1delta2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

glimepiride + metformin SR is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedCancers2026-10-16

Metformin as an Adjunct to Fertility-Sparing Treatment in Atypical Endometrial Hyperplasia and Early-Stage Endometrioid Endometrial Cancer: Narrative Review.

Yordanov Angel A, Tsoneva Eva E, Kostov Stoyan S, Yanachkova Vesselina V et al.

Objective: This study aims to evaluate the potential role of metformin as an adjunct to fertility-sparing treatment strategies for women with atypical endometrial hyperplasia/endometrial intraepithelial neoplasia (AEH/EIN) and early-stage endometrioid endometrial cancer (EEC), with particular emphasis on oncologic and reproductive outcomes. Methods: A systematic search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library was conducted from database inception through May 2026. Eligible studies included randomized controlled trials, prospective studies, and retrospective cohort studies evaluating metformin-containing fertility-sparing treatment regimens in women with AEH/EIN or early-stage EEC. Owing to substantial clinical and methodological heterogeneity in study design, treatment protocols, metformin dosage, follow-up duration, and outcome reporting, a quantitative meta-analysis was considered inappropriate, and the findings were synthesized narratively. Results: Eight publications represented approximately 795 unique patients after accounting for overlapping cohorts. Complete response was reported in 63/92 patients overall (69%) in Acosta-Torres et al., including 23/34 (68%) receiving progestin plus metformin, and in 61/63 (97%) receiving medroxyprogesterone acetate plus metformin in Mitsuhashi et al. Reported recurrence rates ranged from 13.1% to 34.2%. Live births occurred in 2/34 (6%) metformin-treated patients in Acosta-Torres et al., 14/31 (45%) women wished to conceive in Mitsuhashi et al., and 29/79 (36.7%) patients overall in Jing et al. Differences in populations, assessment times, and reproductive denominators limited direct comparisons and attribution of benefit to metformin. Conclusions: Current evidence suggests that metformin may have a promising adjunctive role in fertility-sparing treatment for women with AEH/EIN and early-stage EEC, particularly among patients with obesity, insulin resistance, polycystic ovary syndrome, or other metabolic risk factors. Nevertheless, the overall body of evidence should be interpreted with caution because of substantial heterogeneity across studies, the predominance of retrospective designs, and the limited number of prospective randomized trials. Well-designed multicenter randomized controlled trials are required to define the optimal role of metformin, identify the patients most likely to benefit, and establish standardized treatment strategies before routine incorporation into clinical practice can be recommended.

PMID 42882834
Read full article →
PubMedJournal of clinical medicine2026-10-16

Effects of Metformin on Clinical Outcomes After Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Chen Ting-Yen TY, Su Yu-Chi YC, Lin Yu-Ching YC

Objective: This study investigated the effects of metformin on clinical outcomes after acute ischemic stroke in patients with type 2 diabetes mellitus (T2DM). Methods: PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched for relevant English articles published from database inception to 6 April 2026. Moreover, the reference lists of eligible articles were searched. Studies were included if they focused on patients with T2DM and acute ischemic stroke, indicated whether the patients used metformin before stroke onset, and reported the patients' modified Rankin Scale (mRS) scores after stroke onset. Studies lacking adequate outcome data were excluded. Two reviewers independently extracted relevant data-for example, study details, clinicodemographic characteristics, and poststroke outcomes (mRS scores, National Institutes of Health Stroke Scale [NIHSS] scores, symptomatic intracranial hemorrhage [sICH], and mortality). A senior reviewer was consulted in cases of between-reviewer disagreements. The primary outcome was poststroke mRS score (functional outcome), and the secondary outcomes were poststroke NIHSS scores (neurological severity), sICH, and mortality. Results: Eleven studies met the inclusion criteria. Most studies reported better functional outcomes (mRS scores) and lower NIHSS scores for metformin users than for nonusers. Some studies indicated reduced rates of sICH and mortality among metformin users than among nonusers. Sensitivity analyses generally supported the benefits of metformin. Caution should be exercised when interpreting these findings because the results might have been influenced by variations in study designs, stroke classifications, and renal function reporting. Conclusions: In patients with T2DM, metformin may reduce stroke severity and improve poststroke functional outcomes. To the best of our knowledge, this meta-analysis is the first to investigate the association between metformin use and neurological severity, estimate adjusted ORs for favorable functional outcomes, and highlight publication bias on this topic.

PMID 42881994
Read full article →
PubMedJournal of clinical medicine2026-10-16

Hemodynamic and Metabolic Predictors of Unsuccessful Electrical Cardioversion or Early Atrial Fibrillation Recurrence After Electrical Cardioversion.

Skalska Paulina P, Kurpaska Małgorzata M, Uziębło-Życzkowska Beata B, Krzesiński Paweł P

Background: Rhythm control remains a cornerstone in the management of atrial fibrillation (AF). Although electrical cardioversion (ECV) effectively restores sinus rhythm (SR), its short-term durability is limited. Aims: This study aimed to evaluate the short-term rhythm outcomes after ECV and to identify predictors of failure to achieve or maintain SR within 30 days after ECV, with particular emphasis on the hemodynamic profile of patients with persistent AF. Methods: Ninety-four consecutive patients with persistent AF undergoing elective ECV were prospectively enrolled. Cardiac rhythm was assessed immediately after ECV, at ~24 h, and ~30 days. Laboratory testing, echocardiography, and impedance cardiography (ICG) were performed before ECV. Logistic regression analysis was used to identify predictors of failure to achieve or maintain SR within 30 days after ECV. Results: ECV was initially successful in 80 patients (85.1%), with SR maintained in 76 (80.8%) at 24 h. At 30 days, SR persisted in 49 patients (52.1%), while 43 patients (45.7%) failed to achieve or maintain SR, including 14 patients in whom ECV was unsuccessful and 29 patients who experienced AF recurrence after initially successful ECV; two patients were lost to follow-up. In multivariable analysis, T2DM was independently associated with higher odds of failure to achieve or maintain SR within 30 days after ECV (OR 3.26; 95% CI 1.183-8.978; p = 0.022). Higher TFC values were also independently associated with increased odds of this outcome (OR 1.15; 95% CI 1.017-1.291; p = 0.025). In contrast, the presence of hypertension was associated with lower odds of this outcome (OR 0.30; 95% CI 0.094-0.947; p = 0.040). Among hemodynamic parameters, only TFC was independently associated with the outcome, whereas echocardiographic parameters did not differ between groups. Conclusions: Even in a relatively low-risk population without advanced comorbidity burden, failure to achieve or maintain SR after ECV remains frequent. T2DM and elevated TFC were independently associated with failure to achieve or maintain SR, while hypertension was associated with a lower risk. These findings suggest that metabolic and hemodynamic abnormalities may provide prognostic information beyond that captured by conventional echocardiography.

PMID 42882130
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Correction: Yang et al. Molecular Mechanism of Metformin Regulating the Regeneration of Planarian Dugesia japonica Through miR-27b. Int. J. Mol. Sci. 2025, 26, 7092.

Yang Kexin K, Feng Minmin M, Zhang Chunmei C, Zhao Zelong Z et al.

In the original publication [...].

PMID 42884187
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

Antifungal Efficacy and Chemical Profiles of Salvia, Oregano, and Laurus Essential Oils Against Mold Species Associated with Caciocavallo Cheese Spoilage.

Akram Shazia S, Brandimarte Beatrice B, Basile Giuseppe Natale GN, De Mastro Giuseppe G et al.

Mold contamination is a major cause of spoilage in ripened cheeses. In this study, 171 fungal isolates were recovered from semi-hard Caciocavallo cheese sampled across three seasons. The number of recovered isolates showed a descriptive decrease from summer to winter. Thirty-two representatives were selected for ITS and/or β-tubulin sequencing after morphotype screening. Among these sequenced representatives, Penicillium commune was the most frequent provisional taxonomic designation (8/32; 25.0%), followed by Aspergillus flavus (3/32; 9.4%). Penicillium echinulatum, Fusarium iranicum, Paecilomyces variotii, and Cladosporium-like isolates each accounted for 2/32 (6.3%). ITS-only assignments in taxonomically difficult genera are treated as provisional closest-match designations rather than definitive species identifications. Essential oils (EOs) from three Salvia rosmarinus Spenn. chemotypes (SR-CV2-23, SR-CV3-23, and SR-CV6-23), oregano cv. Carva (Origanum vulgare L. subsp. viridulum (Martrin-Donos) Nyman × O. vulgare L. subsp. hirtum Ietswaart; Ov-C-23), and Laurus nobilis L. (Ln-23) were chemically characterized and evaluated for their antifungal activity against mold species associated with Caciocavallo cheese spoilage. GC-MS showed that the rosemary EOs were rich in camphor, α-pinene, and 1,8-cineole; Ov-C-23 contained 83.95% carvacrol; and Ln-23 contained mainly 1,8-cineole, linalool, and bornyl acetate. All EOs exhibited concentration-dependent antifungal activity, with spore germination generally more sensitive than mycelial growth. At 0.35% (v/v), SR-CV2-23 showed the broadest observed in-vitro activity, whereas Ov-C-23 produced the highest observed inhibition of A. alternata mycelial growth. CFDA/PI confocal microscopy showed the largest relative shift toward reduced metabolic activity and membrane compromise after SR-CV3-23 treatment. In-vitro assays and cheese-slice experiment used different quantitative endpoints and were therefore not directly compared. Ov-C-23 produced the highest observed reduction in visible colonies in the cheese slice model. These EOs may contribute to integrated mold control strategies, but practical application requires further validation under industrial conditions.

PMID 42883201
Read full article →
PubMedOncotarget2026-10-16

WIN-MTB-2024002 - WIN International Molecular Tumor Board: A 52-year-old female with unmeasurable Stage IIIc colon cancer.

El-Deiry Wafik S WS, Hernando-Calvo Alberto A, Magidi Shai S, Bresson Catherine C et al.

Copyright: © 2026 El-Deiry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with a complex molecular profile that impacts tumor behavior and treatment response. This case report discusses a 52-year-old female diagnosed with Stage IIIc colon cancer, exhibiting KRAS, TP53, IDH1, and APC mutations, as well as a tumor microenvironment with high PD-L1 expression and elevated VEGFR1 and VEGFR3. Despite surgical resection and adjuvant treatment which included FOLFOX, FOLFIRI with bevacizumab and local radiation, the patient’s disease was difficult to track due to small, non-FDG-avid lymph nodes in the aortocaval region and persistent circulating tumor DNA (ctDNA). Following a review by an international Molecular Tumor Board (MTB), maintenance therapy options were discussed, including the personalized combinations of regorafenib, sulindac, and metformin, or fruquintinib, sulindac, and metformin, based on the patient’s molecular alterations. Alternatively, 5-FU with or without bevacizumab was suggested. In the event of relapse, the MTB recommended the combination of regorafenib, sulindac, and metformin, with the addition of trametinib and ivosidenib. The combination of regorafenib, ipilimumab, and nivolumab (RIN) was also considered due to the patient’s high PD-L1 expression. Further clinical trial options, such as pan-RAF inhibitors, NK cell agonists, and TAS-102 with bevacizumab, were also discussed. Additionally, the potential combination of PD-1 and TGFβ inhibitors was explored. This case underscores the critical role of molecular profiling in tailoring personalized treatment strategies for advanced CRC, providing novel avenues for managing recurrent disease, even in the absence of measurable disease.

PMID 42885719
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about glimepiride + metformin SR